Curtailing the High Rate of Late-Stage Attrition of Investigational Therapeutics Against Unprecedented Targets in Patients with Lung and Other Malignancies | Citedby Results | Clinical Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Curtailing the High Rate of Late-Stage Attrition of Investigational Therapeutics Against Unprecedented Targets in Patients with Lung and Other Malignancies

Clin Cancer Res (2004) 10 (12): 4220s–4226s.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Death receptors 4/5 mediate tumour sensitivity to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer

Lin Yang
Jiahong Yi
Wenzhuo He
Pengfei Kong
Qiankun Xie
Yanan Jin
Zhenchong Xiong
Liangping Xia

British Journal of Cancer (2024) 131 (2): 334.

Engineered stem cells targeting multiple cell surface receptors in tumors

Sanam L. Kavari
Khalid Shah

Stem Cells (2020) 38 (1): 34.

Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

Jian-Feng Lu
Erik Rasmussen
Beth Y. Karlan
Ignace B. Vergote
Lynn Navale
Mita Kuchimanchi
Rebeca Melara
Daniel E. Stepan
David M. Weinreich
Yu-Nien Sun

Cancer Chemotherapy and Pharmacology (2012) 69 (5): 1135.

Immunoconjugates Against Solid Tumors: Mind the Gap

A D Ricart

Clinical Pharmacology & Therapeutics (2011) 89 (4): 513.

Microfluidic cell arrays in tumor analysis: new prospects for integrated cytomics

Donald Wlodkowic
Jonathan M Cooper

Expert Review of Molecular Diagnostics (2010) 10 (4): 521.

Microfluidics: Emerging prospects for anti-cancer drug screening

Donald Wlodkowic

World Journal of Clinical Oncology (2010) 1 (1): 18.

Microfabricated analytical systems for integrated cancer cytomics

Donald Wlodkowic
Jonathan M. Cooper

Analytical and Bioanalytical Chemistry (2010) 398 (1): 193.

Systematic Survey of Therapeutic Trials for Metastatic Colorectal Cancer: Room for Improvement in the Critical Pathway

Scott Kopetz
Michael Overman
David Z. Chang
Katrina Y. Glover
Imad Shureiqi
Robert A. Wolff
James L. Abbruzzese
Cathy Eng

Journal of Clinical Oncology (2008) 26 (12): 2000.

Directing cancer cells to self-destruct with pro-apoptotic receptor agonists

Avi Ashkenazi

Nature Reviews Drug Discovery (2008) 7 (12): 1001.

Genome-wide screening for drug discovery and companion diagnostics

Allen D Roses

Expert Opinion on Drug Discovery (2007) 2 (4): 489.

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Heinz-Josef Lenz
Eric Van Cutsem
Shirin Khambata-Ford
Robert J. Mayer
Philip Gold
Philip Stella
Barry Mirtsching
Allen L. Cohn
Andrew W. Pippas
Nozar Azarnia
Zenta Tsuchihashi
David J. Mauro
Eric K. Rowinsky

Journal of Clinical Oncology (2006) 24 (30): 4914.

Lately, It Occurs to Me What a Long, Strange Trip It's Been for the Farnesyltransferase Inhibitors

Eric K. Rowinsky

Journal of Clinical Oncology (2006) 24 (19): 2981.

Targeting the molecular target of rapamycin (mTOR)

Eric K Rowinsky

Current Opinion in Oncology (2004) 16 (6): 564.

Effect of Epidermal Growth Factor Receptor Mutations on the Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Target-Based Populations for Target-Based Drugs

Emiliano Calvo
Manuel K. Rowinsky

Clinical Lung Cancer (2004) 6: S35.